Nasdaq

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Nasdaq

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in ...
BioWorld

Alterity develops novel MRI biomarker to track disease progression in MSA

Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), which looks to be a more reliable biomarker for tracking disease progression ...
The American Journal of Managed Care

MRI Study Reveals Hypothalamic Atrophy Across Multiple Subregions in Narcolepsy Type 1

High-resolution 3T T1 MRI with FreeSurfer v7 segmentation identified smaller whole hypothalamic volume in narcolepsy type 1 after adjustment for age, sex, and intracranial volume. Subregional analysis ...